Promising data for MaaT033 in ALS

MaaT Pharma has reported positive results from its Phase 1b trial of MaaT033 for Amyotrophic Lateral Sclerosis (ALS). The trial, conducted at two centers in France, confirmed the safety and tolerability of MaaT033.

Treatment showed rapid establishment of specific bacterial species, especially in the first month, and slower disease progression, although the results require cautious interpretation. Neurofilament levels remained stable after 84 days of follow-up.

Recommendations have been made for a Phase 2 trial, highlighting the broader potential of microbial modulation in neurodegenerative diseases. MaaT Pharma is now seeking partners to support the development of therapeutic solutions for ALS.